NJ Bio, Inc. and Charles River Laboratories, Inc. announced a strategic alliance to offer complementary services to clients including early development and optimization to manufacturing of antibody drug conjugates (ADCs).
It is well known that the path of bringing ADCs to market is an intricate and complex field that requires expert navigation skills. It involves development and manufacturing processes of antibodies (Abs), cytotoxic payloads, linkers, linker-payloads, their conjugation to ADCs, and preclinical and clinical validations. The biggest benefit of the Charles River and NJ Bio alliance is that clients can receive seamless complementary services to enhance outcomes and accelerate time-to-market for their ADCs. Today, innovation has become a necessity to improve the safety and efficacy profiles of ADCs. Another advantage of this alliance to clients is Charles River’s ability to discover innovative engineered Abs while NJ Bio will synthesize and manufacture novel linkers, payloads, or linker-payloads, and ADCs form its GMP facility.